/PRE
PRE Stock - Prenetics Global Limited
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$17.48+6.00%
+$0.99 (+6.00%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $19.23
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$17.31 – $17.65
TARGET (TP)$20.10
STOP LOSS$16.08
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.34
52W High$17.99
52W Low$3.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $30.62M | $21.74M | $13.16M | $12.53M | $65.18M |
| Gross Profit | $15.40M | $8.83M | $3.62M | $3.60M | $26.34M |
| Gross Margin | 50.3% | 40.6% | 27.5% | 28.7% | 40.4% |
| Operating Income | $-48,144,000 | $-51,906,718 | $-66,022,000 | $-56,661,847 | $-995,126 |
| Net Income | $-46,304,000 | $-62,723,871 | $-190,454,000 | $-174,009,273 | $-1,939,689 |
| Net Margin | -151.2% | -288.5% | -1446.8% | -1388.4% | -3.0% |
| EPS | $-3.64 | $-5.58 | $-37.57 | $-47.04 | $-0.26 |
Company Overview
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$7
Average Target
↓ 60.0% Downside
Now
$7
Low
$7
Average
$7
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 18th 2023 | Cantor Fitzgerald | Initiation | Overweight | $7 |
| July 12th 2022 | Citigroup | Initiation | Buy | - |
Earnings History & Surprises
PREBeat Rate
64%
Last 14 quarters
Avg Surprise
+54.9%
EPS vs Estimate
Beats / Misses
9/5
Last 12 quarters
Latest EPS
$-0.41
Q4 2025
EPS Surprise History
Q1 24
+118.8%
$0.90vs$-4.80
Q2 24
+89.2%
$-0.52vs$-4.80
Q3 24
+83.9%
$-0.15vs$-0.93
Q4 24
-2.3%
$-0.88vs$-0.86
Q1 25
-30.6%
$-0.94vs$-0.72
Q3 25
No data
Q3 25
-15.5%
$-0.82vs$-0.71
Q4 25
+25.5%
$-0.41vs$-0.55
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.55 | $-0.41 | +25.5% | ✓ BEAT |
Q3 2025 | Sep 12, 2025 | $-0.71 | $-0.82 | -15.5% | ✗ MISS |
Q3 2025 | Aug 22, 2025 | — | $-0.80 | — | — |
Q1 2025 | Mar 5, 2025 | $-0.72 | $-0.94 | -30.6% | ✗ MISS |
Q4 2024 | Oct 7, 2024 | $-0.86 | $-0.88 | -2.3% | ✗ MISS |
Q3 2024 | Sep 27, 2024 | $-0.93 | $-0.15 | +83.9% | ✓ BEAT |
Q2 2024 | Apr 1, 2024 | $-4.80 | $-0.52 | +89.2% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $-4.80 | $0.90 | +118.8% | ✓ BEAT |
Q4 2023 | Nov 20, 2023 | $-0.82 | $-0.04 | +95.1% | ✓ BEAT |
Q3 2023 | Sep 15, 2023 | $-0.05 | $-0.15 | -200.0% | ✗ MISS |
Q2 2023 | Jun 5, 2023 | $-0.06 | $-0.60 | -900.0% | ✗ MISS |
Q1 2023 | Mar 14, 2023 | $0.09 | $0.90 | +900.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-1.95 | $4.50 | +330.8% | ✓ BEAT |
Q3 2022 | Sep 9, 2022 | $-0.62 | $0.60 | +196.8% | ✓ BEAT |
Q2 2022 | May 17, 2022 | $-19.20 | $-4.46 | +76.8% | ✓ BEAT |
Q1 2022 | Mar 4, 2022 | — | $-10.87 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-11.59 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.32 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.26 | — | — |
Latest News
Prenetics Global's Executives Acquire ~$1.4M Common Shares
📈 PositiveBenzinga•Nov 24, 2025, 12:33 PM
CORRECTION: Prenetics Global Affirms FY2025 Sales Guidance of $90.000M-$100.000M vs $99.200M Est
➖ NeutralBenzinga•Nov 10, 2025, 01:34 PM
CORRECTION: Prenetics Global Raises FY2025 Sales Guidance from $85.000M-$100.000M to $90.000M-$100.000M vs $99.20M Est
➖ NeutralBenzinga•Nov 10, 2025, 01:29 PM
Prenetics Global Affirms FY2025 Sales Guidance of $90.000M-$100.000M vs $186.700M Est
📉 NegativeBenzinga•Nov 10, 2025, 12:48 PM
Prenetics Global Q3 EPS $(0.41) Beats $(0.65) Estimate, Sales $23.555M Miss $25.200M Estimate
➖ NeutralBenzinga•Nov 10, 2025, 12:33 PM
Prenetics Global Limited Announces Its IM8 Health And Longevity Brand Achieved A Record $108M In Annualized Recurring Revenue In October
📈 PositiveBenzinga•Nov 4, 2025, 01:06 PM
Cantor Fitzgerald Maintains Overweight on Prenetics Global, Raises Price Target to $32
📈 PositiveBenzinga•Oct 29, 2025, 02:24 PM
Prenetics Global shares are trading lower after the company announced a $48 million best efforts public offering.
📉 NegativeBenzinga•Oct 27, 2025, 03:00 PM
Prenetics Prices $48M Best Efforts Public Offering Of 2,992,596 Shares And Warrants At A Combined Price Of $16.08
➖ NeutralBenzinga•Oct 27, 2025, 01:55 PM
Reported Earlier: Prenetics Global Limited Launches Daily Ultimate Longevity From Its Rapidly Scaling IM8 Health Brand
📈 PositiveBenzinga•Oct 8, 2025, 02:27 PM
Prenetics Global shares are trading higher. The company reported Q2 financial results.
📈 PositiveBenzinga•Sep 12, 2025, 12:44 PM
Prenetics Sees FY25 Revenue $85M-$100M
➖ NeutralBenzinga•Sep 12, 2025, 12:35 PM
Prenetics Global Q2 Continuing EPS $(0.82) Misses $(0.65) Estimate, Sales $17.68M Miss $24.10M Estimate
📉 NegativeBenzinga•Sep 12, 2025, 12:34 PM
Frequently Asked Questions about PRE
What is PRE's current stock price?
Prenetics Global Limited (PRE) is currently trading at $17.48 per share. The stock has moved +6.00% today.
What is the analyst price target for PRE?
No analyst price targets are currently available for this stock.
What sector is Prenetics Global Limited in?
Prenetics Global Limited operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is PRE's market cap?
Prenetics Global Limited has a market capitalization of $0.23 billion, making it a small-cap company.
Does PRE pay dividends?
No, Prenetics Global Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
ATLN
Atlantic International Corp.
$1.30
Mkt Cap: $0.1B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
MXCT
MaxCyte, Inc.
$1.50
Mkt Cap: $0.2B
OSUR
OraSure Technologies, Inc.
$2.39
Mkt Cap: $0.2B
PROF
Profound Medical Corp.
$7.63
Mkt Cap: $0.2B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
STIM
Neuronetics, Inc.
$1.40
Mkt Cap: $0.1B
TLSI
TriSalus Life Sciences, Inc.
$7.42
Mkt Cap: $0.2B
Explore stocks similar to PRE for comparison